A Phase II Randomized Clinical Trial of Intravitreal Bevacizumab for Diabetic Macular Edema - Scott, Ingrid U; Edwards, Allison R; Beck, Roy W; Bressler, Neil M; Chan, Clement K; Elman, Michael J; Friedman, Scott M; Greven, Craig Michael; Maturi, Raj K; Pieramici, Dante J; Shami, Michel; Singerman, Lawrence J; et al. (Ophthalmology (Rochester, Minn.), 2007)
Keywords: Aged; Angiogenesis Inhibitors - adverse effects; Angiogenesis Inhibitors - therapeutic use; Antibodies, Monoclonal - adverse effects; Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Humanized; Bevacizumab; Biological and medical sciences; Combined Modality Therapy; Diabetes. Impaired glucose tolerance; Diabetic Retinopathy - diagnosis; Diabetic Retinopathy - drug therapy; Endocrine pancreas. Apud cells (diseases); Endocrinopathies; Etiopathogenesis. Screening. Investigations. Target tissue resistance; Female; Humans; Injections; Laser Coagulation; Macular Edema - diagnosis; Macular Edema - drug therapy; Male; Medical sciences; Middle Aged; Miscellaneous; Ophthalmology; Pilot Projects; Retina - drug effects; Retina - pathology; Tomography, Optical Coherence; Vascular Endothelial Growth Factor A - antagonists & inhibitors; Visual Acuity - drug effects; Vitreous Body; Endocrinopathy; Macula; Edema; Randomization; Diabetes mellitus; Phase II trial; Vitreous body; Ophthalmology